Tranexamic Acid: A Game Changer for Trauma Care
- John Gomez
- Oct 3, 2025
- 3 min read
1. TXA is Beneficial – but Only if Timely and Appropriate
The new consensus highlights that TXA reduces mortality when administered to trauma patients with hemorrhagic shock, provided it is given within 3 hours of injury. The earlier, the better.
However, the statement emphasizes that TXA should only be given after life-saving priorities such as airway management, hemorrhage control, and rapid transport are underway.
2. Two Acceptable Dosing Strategies
The statement recognizes two effective dosing options for EMS:
Traditional regimen: 1 g IV/IO bolus followed by a 1 g infusion over 8 hours.
Simplified regimen: A single 2 g IV/IO dose, given as a slow push or short infusion.
Both regimens are now acceptable, giving systems flexibility depending on logistics, resources, and transport times.
3. TXA is Adjunctive, Not Definitive
The authors stress that TXA is not a substitute for hemorrhage control. Direct pressure, tourniquets, hemostatic dressings, and rapid transport to a trauma center remain paramount. TXA is a supportive tool, not a magic bullet.
4. EMS Implementation Matters
For agencies, this update is a call to:
Update protocols to reflect the new evidence.
Train crews on indications, contraindications, and dosing flexibility.
Stock appropriately and ensure TXA is readily available for rapid deployment.
5. TXA Contraindications
Children Under 15 - We don’t routinely give TXA to children under 15 because the big trauma trials (like CRASH-2 and CRASH-3) excluded pediatric patients, so the evidence for benefit just isn’t there. Kids also have different clotting physiology and drug handling than adults, which makes simple weight-based extrapolation less reliable. TXA is widely used in pediatric surgery, but in trauma care, it remains off-label, and most EMS protocols avoid it until more pediatric-specific data is available.
Isolated Traumatic Brain Injury (TBI) - The key word here is isolated. Meaning if you suspect your patient has a brain bleed and no other uncontrolled hemorrhaging, you should avoid the use of TXA. To be clear, if you have a patient with multi-system trauma, where a TBI is one of several injuries, you may wish to consider the use of TXA.
Isolated Spinal Cord Injury - Much like an isolated TBI, you should not use TXA on patients who have a suspected isolated spinal cord injury without other signs of uncontrollable trauma.
Controlled Extremity Trauma - Patients who have a traumatic injury to only an extremity, that is controlled through either direct pressure or the application of tourniquets, are not considered candidates for TXA.
Why This Matters for You
TXA isn’t new, but this joint position statement solidifies its place in the EMS toolbox with strong consensus. For medics, the takeaway is clear: if your trauma patient is in hemorrhagic shock, TXA should be part of your resuscitation plan—as soon as the basics are secured.
To Do List:
Update your protocol(s).
Update your mindset.
TXA isn’t optional anymore—it’s a standard tool in hemorrhage control.
The Future of TXA in EMS
As we look ahead, the integration of TXA into our protocols is not just a trend; it’s a necessity. The evidence is compelling. The lives we save depend on our ability to adapt and implement these guidelines effectively.
Conclusion: Embrace the Change
In the fast-paced world of EMS, we must be agile. The landscape of trauma care is evolving, and so must we. Embrace TXA as a vital part of your toolkit. It’s not just about following protocols; it’s about saving lives.
References
CRASH-2 trial collaborators. "The CRASH-2 trial: a randomized controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients." Health Technol Assess. 2013;17(10):1–79. doi:10.3310/hta17100. PubMed
CRASH-3 trial collaborators. "Effects of tranexamic acid on death, disability, vascular occlusive events, and other morbidities in patients with traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial." Lancet. 2019;394(10210):1713–1723. doi:10.1016/S0140-6736(19)32233-0. The Lancet
Roberts I, Shakur H, Afolabi A, et al. "The importance of early treatment with tranexamic acid in bleeding: an exploration of the time-dependent effect of treatment on mortality." Lancet. 2011;377(9771):1096–1101. doi:10.1016/S0140-6736(11)60278-X. ScienceDirect
Gayet-Ageron A, Ker K, Shakur H, et al. "Exploration of the CRASH-2 trial: a multicenter, randomized, placebo-controlled trial of tranexamic acid in bleeding trauma patients: time-dependent effect of tranexamic acid on mortality." Trials. 2013;14:174. doi:10.1186/1745-6215-14-174. Trials Journal
EMRA. "Does TXA MATTER When Your Patients CRASH?" EM Resident. Published 2020. EMRA.org
London School of Hygiene & Tropical Medicine. "CRASH-3 Trial Results." Published 2019. CRASH-3 Blog
Comments